Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ruiwen Zhang
Texas Tech University Health Scis Center, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Rosalind Franklin University of Medicine and Science
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
John Buolamwini, PhD, has been awarded a patent that is related to the research involved in this project. In addition, Dr. Buolamwini owns a portion of QuesRema Enterprises LLC, a for¬profit start¬up company that has acquired a license for that patent involved in this research and that company seeks to commercialize that patent. QuesRema is a non-publicly traded entity valued at
Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy
Pancreatic cancer has low survival rate and short survival time; there is an urgent need for the development of effective and safe therapy for this disease. The applicants have recently discovered a novel class of anticancer agents that exert anti-pancreatic cancer activity through targeting two cancer-causing genes, MDM2 and �-catenin. This project will test the lead compound (called SP141) for its therapeutic efficacy and safety in clinically relevant pancreatic cancer models and the expected results would have a major impact on patient care and public health by preparing this compound for entering clinical trials.
Filed on December 27, 2016.
Tell us what you know about Ruiwen Zhang's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.